Elidel Labeling (Clarification)
This article was originally published in The Pink Sheet Daily
Executive Summary
An Oct. 18 1story in "The Pink Sheet" DAILY on declining sales for Novartis' eczema treatment Elidel (pimecrolimus) did not describe with sufficient clarity the status of discussions between the firm and FDA on labeling changes
You may also be interested in...
Elidel Sales Fall In Q3 On Fewer U.S. Prescriptions, Novartis Says
Sales of Novartis' eczema treatment Elidel (pimecrolimus) fell 36% to $53 mil. in the third quarter on fewer U.S. prescriptions, Novartis reported Oct. 18
Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk
Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.